Arrowhead Pharmaceuticals receives $200 million from Sarepta milestone Nov 24, 2025 07:30AM
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics Nov 24, 2025 07:30AM
Arrowhead receives $100 million milestone from Sarepta for ARO-DM1 study Jul 28, 2025 07:30AM
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics Jul 28, 2025 07:30AM
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT Jul 22, 2025 04:00PM
View Older Stories

Jul 21, 2025 02:08PM ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 19, 2025 02:16PM ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 18, 2025 02:10PM ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 16, 2025 04:57PM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 15, 2025 04:51PM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 13, 2025 09:31AM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 11, 2025 08:42PM ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 10, 2025 08:37PM ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 9, 2025 06:07PM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 8, 2025 06:02PM ROSEN, A LONGSTANDING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 6, 2025 10:17AM ROSEN, A LONGSTANDING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 5, 2025 10:37AM ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 3, 2025 11:54AM ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jul 1, 2025 01:21PM TOP RANKED ROSEN LAW FIRM Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jun 30, 2025 12:32PM ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
Jun 29, 2025 12:18PM ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
May 6, 2025 04:05PM Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
Feb 26, 2025 04:05PM Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
Feb 12, 2025 08:30AM Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
Feb 10, 2025 08:31AM Arrowhead Pharmaceuticals (ARWR) Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics (SRPT)
Feb 10, 2025 08:30AM Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
Dec 31, 2024 04:10PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 18, 2024 08:30AM Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Nov 29, 2024 04:10PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 26, 2024 07:00AM Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
Nov 6, 2024 04:05PM Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
Oct 31, 2024 04:10PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 23, 2024 08:30AM Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
Sep 30, 2024 04:39PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 26, 2024 08:30AM Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
Sep 16, 2024 08:31AM Sarepta Therapeutics (SRPT) Appoints Deirdre Connelly to its Board
Sep 16, 2024 08:30AM Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
Sep 5, 2024 09:00AM Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
Aug 30, 2024 04:10PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 30, 2024 08:30AM Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Aug 7, 2024 04:05PM Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
Jul 31, 2024 04:15PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 29, 2024 07:00AM Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
Jun 28, 2024 06:30PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 20, 2024 05:02PM Sarepta Therapeutics (SRPT) Announces Expanded FDA Approval of ELEVIDYS
Jun 20, 2024 05:02PM Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
May 31, 2024 05:45PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 3, 2024 10:07AM Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
May 1, 2024 04:05PM Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments
Apr 30, 2024 06:38PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 24, 2024 08:30AM Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
Mar 29, 2024 04:00PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 4, 2024 08:30AM Sarepta Therapeutics to Present at Upcoming Investor Conferences
Feb 29, 2024 06:16PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 29, 2024 09:00AM Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
View Older Stories